苄氧羰基-DL-beta-苯丙氨酸 | 14440-98-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 中文名称: 苄氧羰基-DL-beta-苯丙氨酸
• 中文别名: Cbz-DL-β-苯丙氨酸
• 英文名称: N-(benzyloxycarbonyl)-DL-3-amino-3-phenylpropionic acid
• 英文别名: 3-(benzyloxycarbonylamino)-3-phenylpropanoic acid；N-Benzyloxycarbonyl-DL-β-phenyl-β-Ala；3-benzyloxycarbonylamino-3-phenyl-propionic acid；3-Benzyloxycarbonylamino-3-phenyl-propionsaeure；3-phenyl-3-[[(phenylmethoxy)carbonyl]-amino]propionic acid；D,L-N-Cbz-3-amino-3-phenyl propionic acid；3-{[(Benzyloxy)carbonyl]amino}-3-phenylpropanoic acid；3-phenyl-3-(phenylmethoxycarbonylamino)propanoic acid
• CAS: 14440-98-3
• 化学式: C₁₇H₁₇NO₄
• mdl: MFCD03109892
• 分子量: 299.326
• InChiKey: POJLWVWXBAHGGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.176
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  苄氧羰基-DL-beta-苯丙氨酸 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 3-benzyloxycarbonylamino-3-phenyl-propionyl chloride
  参考文献：
  名称：

  Highly Diastereoselective Alkylation of Perhydropyrimidin-4-ones Directed toward the Synthesis of .alpha.-Substituted .beta.-Amino Acids. 2.

  摘要：

  The alkylation of several enantiomerically pure perhydropyrimidin-4-ones at C-5 is described. For the methylation reaction, mixtures of 5,6-trans- and cis-disubstituted adducts were obtained with high diastereomeric ratios, whereas only the 5,6-trans-disubstituted products were obtained with larger alkylating agents. The dialkylation reaction at C-5 was also studied, and the 5,6-cis-trisubstituted product was preferentially formed. Acidic,hydrolysis of 5,6-trans-disubstituted perhydropyrimidin-4-ones furnished the corresponding beta-amino acid hydrochlorides in quantitative yield. On cyclization of the amino acids, 5,6-trans-disubstituted azetidin-2-ones were also synthesized.

  DOI：

  10.1021/jo00103a020
• 作为产物：
  描述：

  Cbz-L-苯甘氨酸 在 silver trifluoroacetate N-甲基吗啉 、 氯甲酸乙酯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 0.75h， 生成 苄氧羰基-DL-beta-苯丙氨酸
  参考文献：
  名称：

  1,3-恶唑烷酮-5-酮和1,3-恶唑烷酮-6-酮由二十种常见的α-氨基酸合成N-甲基β-氨基酸的有效方法

  摘要：

  应用N-甲基β-氨基酸通常是潜在合成具有生物活性的修饰的肽和其他寡聚体的应用。先前的工作强调了1，3-恶唑烷-5-酮的还原裂解以合成N-甲基α-氨基酸。从α-氨基酸开始，使用两种方法来制备相应的N-甲基β-氨基酸。首先，α -氨基酸转化为Ñ甲基α -氨基酸由所谓的“-1,3-恶唑-5-酮的策略”，将它们再由同系阿恩特-艾斯特方法，得到Ñ-protected Ñ -甲基β -氨基酸选自20种常见衍生α -氨基酸。这些化合物的制备产率为23–57％（相对于N-甲基α-氨基酸）。在第二种方法中，可以通过Arndt–Eistert方法将12个N保护的α-氨基酸直接同源，然后将所得的β-氨基酸以30–45％的产率转化为1,3-恶二嗪-6-酮。 。最后，还原裂解以41–63％的收率提供了所需的N-甲基β-氨基酸。

  DOI：

  10.1002/hlca.200690235

文献信息

• [EN] MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR<br/>[FR] MODULATEURS DU RÉGULATEUR DE LA CONDUCTANCE TRANSMEMBRANAIRE DE LA FIBROSE KYSTIQUE
  申请人：VERTEX PHARMA

  公开号：WO2021030556A1

  公开（公告）日：2021-02-18

  This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

  这份披露提供了囊性纤维化跨膜传导调节蛋白（CFTR）的调节剂，包含至少一种这样的调节剂的药物组合物，使用这种调节剂和药物组合物治疗囊性纤维化的方法，以及制造这种调节剂的过程。
• Thiadiazole amide MMP inhibitors
  申请人：——

  公开号：US05830869A1

  公开（公告）日：1998-11-03

  The present invention provides novel thiadiazole amide derivatives represented by formula I ##STR1## The compounds of the present invention inhibit various enzymes from the matrix metalloproteinase family, predominantly stromelysins, and hence are useful for the treatment of matrix metallo endoproteinase diseases such as osteoarthritis, rheumatoid arthritis, septic arthritis, osteopenias such as osteoporosis, tumor metastasis, periodontitis, gingivitis, corneal ulceration, dermal ulceration, gastric ulceration, inflammation and other diseases related to connective tissue degradation.

  本发明提供了由式I表示的新型噻二唑酰胺衍生物。本发明的化合物抑制来自基质金属蛋白酶家族的各种酶，主要是胶原酶，因此对于治疗基质金属蛋白酶疾病如骨关节炎、类风湿性关节炎、化脓性关节炎、骨质疏松症如骨质疏松症、肿瘤转移、牙周炎、牙龈炎、角膜溃疡、皮肤溃疡、胃溃疡、炎症和其他与结缔组织降解相关的疾病具有用处。
• [EN] SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS<br/>[FR] DÉRIVÉS D'AZÉTIDINE SUBSTITUÉS EN TANT QUE LIGANDS DE TAAR
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016030310A1

  公开（公告）日：2016-03-03

  The present invention relates to a compound of formula I wherein R1 is hydrogen, methoxy or fluoro; R2/R2' are independently from each other hydrogen, methoxy or fluoro; R3/R4 are independently from each other hydrogen or halogen; R is hydrogen or fluoro; L1 is -CH2-, -NR'-, -0-, -S-, CF2- or CH=; R' is hydrogen or lower alkyl; L2 is a bond, -C(0)NH-, -NH-, -CH2NHC(O)-, -NHC(O)- or -NHC(0)NH-; R is hydrogen, halogen, lower alkoxy, cyano or is phenyl optionally substituted by one or more substituents, selected from halogen, lower alkyl substituted by halogen or lower alkoxy, or is a five or six membered heteroaryl, selected from pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl or pyrazolyl, which heteroaryls are optionally substituted by one or more substituents, selected from halogen, lower alkyl, lower alkoxy, cyano, cycloalkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen or by phenyl substituted by halogen; N is a ring nitrogen atom in position 1 or 2; or to a pharmaceutically suitable acid addition salt thereof. The compounds of formulas I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1 and may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及一种具有以下式I的化合物，其中R1是氢、甲氧基或氟；R2/R2'分别独立地是氢、甲氧基或氟；R3/R4分别独立地是氢或卤素；R是氢或氟；L1是-CH2-、-NR'-、-O-、-S-、CF2-或CH=；R'是氢或较低的烷基；L2是键、-C(0)NH-、-NH-、-CH2NHC(O)-、-NHC(O)-或-NHC(0)NH-；R是氢、卤素、较低的烷氧基、氰基或是苯环，可以选择性地被一个或多个取代基取代，所述取代基选自卤素、被卤素或较低的烷氧基取代的较低烷基、或是被卤素取代的苯环，或是一个五元或六元杂环芳基，选自吡啶基、嘧啶基、吡嗪基、吡啶嗪基或吡唑基，这些杂环芳基可以选择性地被一个或多个取代基取代，所述取代基选自卤素、较低的烷基、较低的烷氧基、氰基、环烷基、被卤素取代的较低烷基、被卤素取代的较低烷氧基或被卤素取代的苯基；N是1或2位置的环氮原子；或其药学上适宜的酸盐。式I的化合物对痕量胺相关受体(TAARs)具有良好的亲和力，特别是对TAAR1，可用于治疗抑郁症、焦虑症、双相情感障碍、注意缺陷多动障碍(ADHD)、与压力有关的障碍、如精神分裂症、帕金森病等神经疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用和代谢障碍，如进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病的治疗。
• Polypeptides. Part VII. Variations of the phenylalanyl position in the C-terminal tetrapeptide amide sequence of the gastrins
  作者：H. Gregory、D. S. Jones、J. S. Morley

  DOI：10.1039/j39680000531

  日期：——

  The synthesis is described of analogues of L-tryptophyl-L-methionyl-L-aspartyl-L-phenylalanine amide (the C-terminal sequence of the gastrins) or its N-benzyloxycarbonyl, -t-butoxycarbonyl, or -carbamoyl derivatives wherein the phenylalanyl residue has undergone replacement by other naturally occuring amino-acyl residues or by αα-disubstituted amino-acyl residues, or has been modified by (a) substitution

  描述了L-色氨酸-L-甲硫酰基-L-天冬氨酰-L-苯丙氨酸酰胺（胃泌素的C-末端序列）或其N-苄氧羰基，-叔丁氧羰基或-氨基甲酰基衍生物的类似物的合成。苯丙氨酰基残基已被其他天然存在的氨基酰基残基或αα-二取代的氨基酰基残基取代，或已通过（a）在对位取代芳环进行修饰，（b）芳环的氢化，（c）亚氨基从α-碳原子转换为β-碳原子，（d）将苯环从β-碳原子转换为α-碳原子，（e）取代β-碳原子上的羟基，或（f）亚氨基的甲基化。
• A novel, microwave-assisted method for the synthesis of alicyclic-condensed 5H-1,4,6,7-tetrahydro-1,4-diazepin-5-ones
  作者：Árpád Balázs、Erik Van der Eycken、Ferenc Fülöp

  DOI：10.1016/j.tetlet.2008.05.034

  日期：2008.7

  An efficient, high-yielding method has been developed for the synthesis of cycloalkane-fused and phenyl-substituted 1,4-diazepin-5-ones from β-amino acids. The process involves the oxidative cleavage of a terminal olefin bond and an acid-catalyzed, microwave-assisted intramolecular condensation step.

  已经开发了一种高效，高产率的方法，用于从β-氨基酸合成环烷烃稠合的和苯基取代的1,4-二氮杂5-5-酮。该方法涉及末端烯烃键的氧化裂解和酸催化的，微波辅助的分子内缩合步骤。